Flexion Therapeutics Inc.'s (Nasdaq: FLXN) pain treatment FX006 failed to
reach statistical significance at the primary endpoint of its Phase 2b
clinical trial. Shares of the specialty pharmaceutical company plummeted $6.98 to close at $22.02.
Flexion's FX006 fails clinical trial
September 09, 2015 at 17:50 PM EDT
